Skip to main content
. Author manuscript; available in PMC: 2023 Oct 10.
Published in final edited form as: J Rheumatol. 2019 Apr 1;47(3):431–440. doi: 10.3899/jrheum.180233

Table 1A.

Baseline characteristics: subjects and treatment factors.

Variables Full Sample First Followup Visit 6-month Visit
Nonresponder Responder Nonresponder Responder
N Values N Values N Values N Values N Values
Demographic/prior knee injury
 Age, yrs, mean (SD) 199 62.8 (10.3) 53 62.6 (9.9) 146 62.9 (10.5) 159 63.4 (10.5) 40 60.5 (9.5)
 Females, frequency (%) 199 105 (52.8) 52 22 (41.5) 146 83 (56.9) 159 83 (52.2) 40 22 (55.0)
Pain
 KOOS pain subscale score (0–100)* 199 44.4 (36.1–55.6) 53 44.4 (38.9–61.1) 146 44.4 (36.1–52.8) 159 44.4 (36.1–55.6) 40 44.4 (36.1–52.8)
 Pain on nominated activity, VAS (0–10 cm)** 190 7.0 (5.6–8.1)¤ 49 7.0 (5.2–8.4) 141 7.0 (5.8–8.0) 152 7.0 (5.5–8.1) 38 7.2 (6.4–8.1)
 Pain in last week VAS (0–10 cm)** 194 6.5 (5.0–8.0)¤ 50 6.8 (3.3–8.0) 144 6.5 (5.0–8.0) 154 6.5 (4.8–8.0) 40 6.5 (5.1–8.1)
 No. pain sites 177 4.0 (2.0–5.0) 47 4.0 (2.0–6.0) 130 3.0 (2.0–5.0) 143 4.0 (2.0–5.0) 34 2.0 (2.0–4.0)
 Chronic widespread pain (ACR), frequency (%) 150 39 (26.0) 38 11 (29.0) 112 28 (25.0) 120 36 (30.0) 30 3 (10.0)
Psychological factors
 HADS anxiety 170 6.5 (3.0–9.0) 45 6.0 (3.0–9.0) 125 7.0 (3.0–9.0) 137 7.0 (3.0–9.0) 33 5.0 (2.0–9.0)
 HADS depression 170 4.0 (2.0–8.0) 45 5.0 (3.0–8.0) 125 4.0 (2.0–7.0) 137 5.0 (2.0–8.0) 33 3.0 (2.0–6.0)
 IPQ-B consequences score 175 6.0 (4.0–8.0) 46 7.0 (4.0–8.0) 129 6.0 (4.0–8.0) 141 7.0 (4.0–8.0) 34 6.0 (4.0–7.0)
 IPQ-B timeline score 172 10.0 (8.0–10.0) 46 10.0 (7.0–10.0) 126 9.0 (8.0–10.0) 139 10.0 (8.0–10.0) 33 8.0 (6.0–10.0)
 IPQ-B personal control score 173 5.0 (2.0–7.0) 45 5.0 (2.0–6.0) 128 4.0 (2.0–7.0) 140 5.0 (2.0–7.0) 33 4.0 (3.0–7.0)
 IPQ-B treatment score 174 8.0 (5.0–10.0) 46 7.0 (5.0–8.0) 128 8.0 (6.0–10.0) 141 8.0 (5.0–10.0) 33 8.0 (7.0–9.0)
 IPQ-B identity score 175 7.0 (6.0–9.0) 46 7.5 (5.0–8.0) 129 7.0 (6.0–9.0) 142 7.0 (6.0–9.0) 33 7.0 (6.0–8.0)
 IPQ-B illness concern score 174 7.0 (5.0–9.0) 46 7.5 (5.0–9.0) 128 7.0 (5.0–9.0) 141 7.0 (5.0–9.0) 33 7.0 (5.0–8.0)
 IPQ-B coherence score 172 8.0 (7.0–10.0) 46 8.0 (6.0–10.0) 126 8.0 (7.0–10.0) 139 8.0 (7.0–10.0) 33 8.0 (7.0–10.0)
 IPQ-B emotional representation score 172 5.0 (2.0–7.0) 46 5.0 (2.0–8.0) 126 5.0 (2.0–7.0) 139 5.0 (2.0–7.0) 33 5.0 (1.0–7.0)
Quality of life
 SF-12 physical component summary, mean (SD) 184 32.3 (8.7) 50 31.7 (8.8) 134 32.5 (8.7) 147 32.2 (8.9) 37 32.6 (8.0)
 SF-12 mental component summary, mean (SD) 184 49.2 (11.7) 50 47.2 (12.8) 134 50.0 (11.2) 147 48.8 (11.8) 37 51.2 (10.9)
Treatment-related factors
 Synovial fluid aspiration, frequency (%) 199 89 (44.7) 53 32 (60.4) 146 57 (39.0) 159 73 (45.9) 40 16 (40.0)
 Ultrasound-guided knee injection, frequency (%) 199 79 (39.7) 53 18 (34.0) 146 61 (41.8) 159 62 (39.0) 40 17 (42.5)
 Clinical-related factors (subset n = 101)
 Quadriceps muscle strength, Nm/kg 98 0.6 (0.4–1.1) 23 0.7 (0.3–1.5) 75 0.6 (0.4–1.1) 77 0.6 (0.3–1.0) 21 1.0 (0.5–1.2)
 Knee range of movement, degrees
  Flexion 101 120.0 (111.0–127.0) 23 122.0 (106.0–127.0) 78 120.0 (112.0–127.0) 79 120.0 (111.0–126.0) 22 121.0 (114.0–128.0)
  Extension 101 172.0 (170.0–176.0) 23 172.0 (170.0–177.0) 78 172.0 (170.0–176.0) 79 172.0 (170.0–176.0) 22 172.0 (170.0–177.0)

Values are median (IQR) unless otherwise specified.

*

KOOS pain subscale is scored from 100 (no pain) to 0 (extreme pain).

**

VAS are scored from 0 (no pain) to 10 (pain as bad as you can imagine).

¤

N < 199 indicates patients not completing this particular element of the questionnaire.

Clinical tests were performed in a subset of 103 patients only; 2 patients did not complete KOOS. KOOS: Knee Injury and Osteoarthritis Outcome Score; VAS: visual analog scale; IQR: interquartile range; HADS: Hospital Anxiety and Depression Scale; IPQ-B: Illness Perception Questionnaire-Brief; SF-12: Medical Outcomes Study Short Form-12; ACR: American College of Rheumatology.